Author: Mary Powers

Research homes in on drug to dampen inflammation fueling life-threatening immune disorder

Researchers know small molecules called cytokines fuel the fire that drives the life-threatening immune disorder hemophagocytic lymphohistiocytosis (HLH). St. Jude investigators recently detailed how the drug ruxolitinib functions like a fuel shut-off valve to dampen the immune response. Treatment was associated with improved survival in mouse models of HLH compared with a targeted HLH cytokine inhibitor. “Results of this preclinical study support including ruxolitinib in future clinical trials,” said corresponding author Kim Nichols, MD, Oncology. The research appeared in the journal Blood. HLH is a family of rare, related and often-fatal immune disorders characterized by a massive accumulation and overactivation...

Read More

Histiocytic disorders are the focus of annual meeting at St. Jude

Imagine parenting a child with a disorder so rare that the correct diagnosis is a challenge. Finding enough other children with the disease for research to improve understanding and treatment is difficult. Generating interest or funding for the work is even tougher. That’s what the families of children diagnosed with histiocytic disorders, such as Langerhans cell histiocytosis (LCH) and hemophagocytic lymphihistiocytosis (HLH), often face. This family of diseases are rare, related and often fatal. While the causes vary or in some cases are still unknown, the disorders share a common feature: Overproduction of white blood cells called histiocytes. The...

Read More

Stay Current on St. Jude News

Subscribe for regular updates on St. Jude leadership, research, and clinical care

Recent Tweets

Recent Videos